Enfusion: The 7 Most Significant Forces Steering Its Performance into 2025 & Beyond!

Enfusion reported a solid third quarter in 2024, demonstrating a 15% year-over-year revenue growth, reaching $51.2 million. This aligns with the company’s focus on executing its long-term strategic initiatives, particularly in expanding its footprint into higher-value market segments. The adjusted EBITDA also showed a positive trend, totaling $11.1 million, equating to a healthy margin of 21.8%. This performance reflects a significant improvement compared to the previous year, driven largely by disciplined cost management and scale efficiencies in SG&A functions.